Tech

RFK Jr. proposes FDA look the other way on unproven peptides, report says

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 16/10/2026, 18:43:24 UTC.

Briefings

Health Secretary Robert F. Kennedy Jr. is advancing an Interim Access Policy for the FDA to ease access to unproven peptide drugs used by his Make America Healthy Again movement. Despite FDA scientists noting these drugs lack sufficient safety and efficacy studies and potential harms, the policy grants enforcement discretion to specialty pharmacies. The Department of Health and Human Services declined to comment on the proposal.

Key points

• The FDA submitted an Interim Access Policy for review by the White House to ease access to unproven peptide drugs.
• The policy grants enforcement discretion to specialty pharmacies, allowing them to avoid agency enforcement on certain peptide drugs.

Context

This policy addresses the FDA's review of unproven peptides popular among Kennedy's Make America Healthy Again movement, where safety and efficacy are not established.

Limitations

The filing notice does not provide details on the proposed policy, and the Department of Health and Human Services declined to comment on the proposal.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 16/10/2026, 19:50:04 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeih7cp5zd5phtg6xhkci7v3ve7by5hdbdysn7p5rqrvkmv7jvzujiq